[French] An overview of early and advanced breast cancers with special focus on staging, molecular subtypes, risk factors and risk stratification, risk of developing breast cancer, and therapeutic options
[French] Key Insights on Early and Metastatic Breast Cancers Read More ยป
[Spanish] An overview of early and advanced breast cancers with special focus on staging, molecular subtypes, risk factors and risk stratification, risk of developing breast cancer, and therapeutic options
[Spanish] Key Insights on Early and Metastatic Breast Cancers Read More ยป
[German] An overview of early and advanced breast cancers with special focus on staging, molecular subtypes, risk factors and risk stratification, risk of developing breast cancer, and therapeutic options
[German] Key Insights on Early and Metastatic Breast Cancers Read More ยป
The research highlights the effectiveness of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors as a new standard treatment for advanced or metastatic breast cancer with positive hormone receptors and HER-2 negative. The combination of CDK4/6 inhibitors with endocrine therapy significantly improves progression-free survival, overall survival, and chemotherapy-free intervals compared to hormonal treatments alone. Further investigation into treatment resistance mechanisms is necessary for future advancements.
Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment Read More ยป
The SONIA trial demonstrated that patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer can achieve noninferior progression-free survival with deferred second-line treatment using CDK 4/6 inhibitors compared to first-line treatment, while also realizing significant cost savings. However, the authors highlight important limitations of the trial and advocate for CDK 4/6 inhibitors to continue as the standard-of-care first-line therapy due to their impact on overall survival.
The SONIA trial shows the power and challenges of academic research Read More ยป
An overview of early and advanced breast cancers with special focus on staging, molecular subtypes, risk factors and risk stratification, risk of developing breast cancer, and therapeutic options
Key Insights on Early and Metastatic Breast Cancers Read More ยป
Dr. Fatima Cardoso discusses two potentially practice-changing studies, focusing on advanced breast cancer treatments and their implications for clinical practice.
December 12 – Dr. Fatima Cardoso Read More ยป
Dr. Gabe S. Sonke discusses various studies on breast cancer treatments, including the effectiveness of new drugs, neoadjuvant chemotherapy strategies, and the benefits of remote symptom monitoring for patients with advanced breast cancer.
December 11 – Dr. Gabe S. Sonke Read More ยป
Dr. Christos Sotiriou highlights the identification of five different subtypes of breast cancer and the application of advanced technologies to analyze tissues and tumors.
December 10 – Dr. Christos Sotiriou Read More ยป
This research introduces CITR-Net, a multi-modality fusion framework that integrates clinicopathologic information with tumor region characteristics to enhance the prediction of neoadjuvant chemotherapy (NACT) response in breast cancer. The framework utilizes advanced techniques to capture and merge features from both imaging and tabular data, demonstrating superior performance in experimental evaluations compared to existing methods, ultimately aiming to improve patient care and prognostic outcomes.
This site is only for use by healthcare professionals.
By continuing to view this site you are confirming that you are a healthcare professional.
Confirm
